SecBot SecBot
SECBOTREPLAY Home › Report › ANAB

ANAB · Q1 rev $30.3M, EPS $0.13

AnaptysBio, Inc. · PRESS-RELEASE filed Nov 12, 2026 at 16:15 ET

At the news

BEARISHIMPACT 4/10

PRESS-RELEASE filed Nov 12, 2026 at 16:15 ET

AnaptysBio reported Q1 FY2027 (Sep 2026) collaboration revenue of $30.3M, below the $33.5M consensus, and GAAP EPS of $0.13, well below the $0.53 consensus estimate. The revenue decline was driven by the absence of a $50M milestone recognized in the year-ago quarter, partially offset by higher Jemperli royalties. The company highlighted the upcoming PDUFA date for Quimilza (Dec 12, 2026) and the pending litigation judgment against GSK/Tesaro (Q4 2026 or Q1 2027) as key catalysts.

  • Collaboration revenue of $30.3M for Q1 FY2027 (Sep 2026), down from $76.3M in the year-ago quarter, missing the $33.5M consensus.
  • GAAP net income from continuing operations of $3.9M ($0.13 per diluted share), down from $56.3M ($1.94 per diluted share) in Q1 FY2026, missing the $0.53 consensus EPS estimate.
  • Cash and investments totaled $153.0M at Sep 30, 2026, down from $164.1M at Jun 30, 2026.
  • Jemperli global net sales reached $1.0B for the nine months ended Sep 30, 2026, up 29% YoY; Anaptys receives 12% royalties on net sales between $1.0B and $1.5B annually.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access